The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor load
Daniele Generali(University of Trieste), Alberto Angeli(Ospedale San Luigi Gonzaga), Alberto Bottini(University of Genoa), S. Tedoldi(Istituti Ospitalieri di Cremona), Giovanni Allevi(Istituti Ospitalieri di Cremona), Sergio Aguggini(Istituti Ospitalieri di Cremona), Marco Tampellini(Ospedale San Luigi Gonzaga), Luigi Dogliotti(Aarhus University Hospital), Marcello Tucci(University of Turin), Manuela Milani(Humanitas University), Alfredo Berruti(Surgical Specialties (Canada)), Simone Bonardi(Istituti Ospitalieri di Cremona), Andrea Dovio(University of Turin)
Cited by 22
Related Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer
|Journal of Clinical Oncology|2005|1.9k
Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study
|Journal of Clinical Oncology|2012|368